Risk score accurately predicts which pregnant and postpartum women would benefit most from PrEP

Risk score accurately predicts which pregnant and postpartum women would benefit most from PrEP

By Michael Carter A risk score based on routine assessments carried out during antenatal care in resource-limited settings can accurately predict which pregnant and breastfeeding women have an especially high risk of infection with HIV and would therefore benefit from pre-exposure prophylaxis (PrEP), investigators report in the online edition of Clinical Infectious Diseases. Predictors of infection with HIV included a partner of unknown HIV status, number of lifetime sexual partners, syphilis, bacterial vaginosis and vaginal…

Read more

A risk assessment tool for identifying pregnant and postpartum women who may benefit from pre-exposure prophylaxis (PrEP)

Abstract only Jillian Pintye1,2, Alison L. Drake1, John Kinuthia4, Jennifer A. Unger1,3, Daniel Matemo4, Renee Heffron1, Ruanne Barnabas1,5,8, Pamela Kohler1,2, R. Scott McClelland1,5,6,7, and Grace John-Stewart1,5,6,8 Abstract Background: An HIV risk assessment tool for pregnant women could identify women who would most benefit from PrEP while minimizing unnecessary PrEP exposure Methods: Data from a prospective study of incident HIV among pregnant/postpartum women in Kenya was randomly divided into derivation (n=654) and validation (n=650) cohorts. A risk score was derived using multivariate Cox proportional hazards…

Read more

Maximizing the potential of a new HIV prevention method: PrEP

Maximizing the potential of a new HIV prevention method: PrEP

Pre-exposure prophylaxis (PrEP)—most often a combination of tenofovir and emtricitabine taken orally as a daily tablet—is extremely effective at preventing HIV infection when taken regularly. The choice of PrEP is recommended for people who are HIV-negative but at high risk of becoming infected. The people who can benefit most from PrEP—including gay men and other men who have sex with men, transgender people, sex workers, serodiscordant couples before the partner living with HIV becomes virally…

Read more

HIV prevention drug Truvada approved

HIV prevention drug Truvada approved

By William George The use of the drug is only for adults who are at a high risk of getting HIV-1. Medicines Control Council (MCC) held their 75th meeting from November 27-28, where Truvada, the HIV prevention drug, was approved. MCC approved the use of the fixed-dose combination of tenofovir disoproxyl fumarate and emtricitabine to include pre-exposure prophylaxis of HIV (commonly referred to as PrEP). Speaking to The Citizen, Popo Maja, the communications officer at the National…

Read more